29641494_14186|t|RSS_IDENT_p_29641494_b_1_3_5
29641494_14186|a| In the current study, another protective effect of maternal melatonin therapy on hypertension is mediating NO system. We found that HF/HS rats had a higher plasma l-citrulline level compared to those in ND/ND rats and this increase was preserved by melatonin. This is in line with previous observations showing that NO deficiency due to impaired l-citrulline conversion to l-arginine contributes to hypertension [ 33 , 34 ]. Our recent studies indicated that maternal melatonin therapy protects against hypertension is related to reduction of plasma levels of ADMA and SDMA and increases of l-arginine-to-ADMA ratio. Because, individually, ADMA and SDMA are inhibitors of NO synthase and the l-arginine-to-ADMA ratios represent NO bioavailability [ 35 ], our data are in agreement with previous studies showing that early treatment with melatonin could restore the ADMAâ€“NO pathway prior to hypertension in favor of NO, to prevent the development of hypertension in spontaneously hypertensive rats [ 17 , 36 ]. Additionally, our current study shows that maternal melatonin therapy significantly increased Nrf2 expression. As we have recently demonstrated in other work [ 37 ], the NRF2 activator dimethyl fumarate reversed combined prenatal dexamethasone exposure and post-weaning high-fat diet-induced increases of ADMA and SDMA concentrations and a decrease in the l-arginine-to-ADMA ratio. Our data suggest that maternal melatonin therapy might activate Nrf2 signaling and restore the ADMA-NO pathway, to protect against HF/HS-induced programmed hypertension.
29641494_14186	81	107	maternal melatonin therapy	Drug	not found
29641494_14186	111	123	hypertension	Disease	DOID:10763
29641494_14186	137	139	NO	Chemical
29641494_14186	162	164	HF	Chemical
29641494_14186	165	167	HS	Chemical
29641494_14186	193	205	l-citrulline	Chemical
29641494_14186	279	288	melatonin	Drug	CHEMBL45
29641494_14186	346	359	NO deficiency	Biomarker
29641494_14186	367	413	impaired l-citrulline conversion to l-arginine	Biomarker
29641494_14186	376	388	l-citrulline	Chemical
29641494_14186	403	413	l-arginine	Chemical
29641494_14186	429	441	hypertension	Disease
29641494_14186	489	515	maternal melatonin therapy	Drug
29641494_14186	533	545	hypertension	Disease
29641494_14186	590	594	ADMA	Chemical
29641494_14186	599	603	SDMA	Chemical
29641494_14186	621	631	l-arginine	Chemical
29641494_14186	635	639	ADMA	Chemical
29641494_14186	670	674	ADMA	Chemical
29641494_14186	679	683	SDMA	Chemical
29641494_14186	702	713	NO synthase	Genefamily	not found
29641494_14186	722	732	l-arginine	Chemical
29641494_14186	736	740	ADMA	Chemical
29641494_14186	758	760	NO	Chemical
29641494_14186	867	876	melatonin	Drug
29641494_14186	895	899	ADMA	Chemical
29641494_14186	900	902	NO	Chemical
29641494_14186	920	932	hypertension	Disease
29641494_14186	945	947	NO	Chemical
29641494_14186	979	991	hypertension	Disease
29641494_14186	1083	1109	maternal melatonin therapy	Drug
29641494_14186	1134	1138	Nrf2	Gene-protein
29641494_14186	1210	1214	NRF2	Gene-protein
29641494_14186	1225	1242	dimethyl fumarate	Chemical
29641494_14186	1270	1283	dexamethasone	Chemical
29641494_14186	1345	1349	ADMA	Chemical
29641494_14186	1354	1358	SDMA	Chemical
29641494_14186	1396	1406	l-arginine	Chemical
29641494_14186	1410	1414	ADMA	Chemical
29641494_14186	1444	1470	maternal melatonin therapy	Drug
29641494_14186	1486	1490	Nrf2	Gene-protein
29641494_14186	1517	1521	ADMA	Chemical
29641494_14186	1522	1524	NO	Chemical
29641494_14186	1553	1555	HF	Chemical
29641494_14186	1553	1590	HF/HS-induced programmed hypertension	Disease	not found
29641494_14186	1556	1558	HS	Chemical

